Drugging the intrinsically disordered transactivation domain of androgen receptor [LNCaP95]
Androgen receptor (AR) is a therapuetic target for prostate cancer. Despite therapuetic approaches  against its ligand-binding domain (LBD), resistance ultimately develops by mechanisms which result in reactivaton of AR signaling. These mechanisms include expression of constitutively active AR that lacks LBD and fueled the discovery of inhibitors to AR's N-terminal intrinsically disordered transactivation domain (TAD). AR-TAD inhibitors are unique as there is a paucity of small molecule inhibitors that bind directly to intriniscally disordered TADs. Here we reveal gene- and cell specific sensitivities in human prostate cancer cells and xenografts to small molecule inhibitors to AR-TAD. These inhibitors have unique biological functions compared to an AR-LBD inhibitor, including being more efficacious in vivo in a non-castrate setting of androgen-sensitive prostate cancer. These data support a new therapuetic approach for prostate cancer and more broadly reveal the sensitivity of an IDR TAD to small molecule inhibitors on gene expression and cellular pathways. Overall design: To better characterize the differences between AR-TAD inhibitors (ARTADI) EPI-002 and BU3-12 from  the AR-LBD inhibitor enzalutamide, we performed whole genome transcriptional profiling on LNCaP95 cells in the absence of androgen to look at genes regulated by constitutively active AR splice variant (AR-V7). A control group (those samples treated with DMSO vehicle in the absence of synthetic androgen R1881) was included.  Three biological replicates were included for each group.